Call Us for Support
+91 9654860915
Google Reviews
4.8
Call Us for Support
+91 9654860915
Sourced directly from the authorized manufacturer network to ensure authenticity and quality.
You can also access detailed information by clicking Login in the website header.
Supplied with complete CDSCO-approved import and customs documentation, including Form 12A & 12B, CDEC, GST Bill of Entry, Commercial Invoice, and Packing List.
Manufacturer / Innovator:
Netherlands
Regulatory Approval:
Your Trustedworthy Partner For Named Patient Program
Over a decade of trusted expertise in Named Patient Access to innovative and life-saving medicines.
100% CDSCO-compliant processes ensuring safe, ethical, and responsible medicine access.
Medicines sourced from authorized manufacturers with full batch traceability.
EU-GDP compliant warehousing for secure, quality-controlled global distribution.
Temperature-controlled logistics ensuring safe, reliable, and timely medicine delivery.
Amondys 45 (casimersen) is an antisense oligonucleotide that helps skip a mutated section of the DMD gene's pre-mRNA, enabling production of a shorter but functional dystrophin protein. It is indicated for the treatment of:
This indication is approved under accelerated approval based on an increase in dystrophin production observed with treatment; a corresponding clinical benefit has not yet been fully confirmed. It is a prescription medicine and must be used under the supervision of a qualified neurologist, following genetic confirmation of exon 45-amenable mutation status.
This information is not a treatment plan. For personalized medical advice, consult your doctor and refer to the full prescribing information.
Step 1 – Search & request your medicine: The patient or treating doctor submits a request with basic details to initiate the access process.
Step 2 – Verification & eligibility review: The team verifies availability and reviews eligibility against regulatory and clinical requirements to ensure a compliant pathway.
Step 3 – Receive quote & delivery timeline: A transparent quotation is shared, covering medicine cost, logistics, and a clear delivery timeline.
Step 4 – Regulatory approval process: Assistance is provided to secure the approvals and documentation required for legal cross-border access.
Step 5 – Temperature-controlled import & handling: The medicine is sourced and transported under strict GDP-compliant, cold-chain conditions to maintain product integrity.
Step 6 – Secure delivery: The medicine is delivered to the patient or treating hospital, with updates provided at each stage.
Note: From request to delivery, every step is designed to ensure your treatment reaches you safely, compliantly, and without unnecessary delays.
Amondys 45 (casimersen) injection may be imported in the patient's name only, by patients or government hospitals, in line with India's import regulations for unapproved medicines. The following documentation is required:
The order is confirmed only after receipt and verification of a valid prescription from the doctor and, if applicable, an import permit.
Amondys 45 (casimersen injection) is a prescription medicine that legally requires a doctor's prescription to be dispensed. As of current publicly available information, Amondys 45 is not commercially marketed in India.
However, patients in India can legally access Amondys 45 through the Named Patient Program (NPP) — an import provision that allows a medicine not yet registered in India to be imported in the name of a specific patient for their personal treatment, under a valid prescription.
Amondys 45 received accelerated US FDA approval in 2021, ensuring full transparency throughout the process.
Amondys 45 can be made available to patients, doctors, and hospitals across major cities in India, including Gurgaon, Delhi, Bangalore, Mumbai, Navi Mumbai, Thane, Hyderabad, Mysore, Kerala, Chennai, Coimbatore, Madurai, Kolkata, Ahmedabad, Surat, Vadodara, Pune, Nagpur, Nashik, Jaipur, Udaipur, Lucknow, Kanpur, Gorakhpur, Chandigarh, Mohali, Faridabad, Noida, Ghaziabad, Kochi, Trivandrum, Kozhikode, Thrissur, Kannur, Mangalore, Bhubaneswar, Patna, Ranchi, Raipur, Guwahati, Visakhapatnam, Vijayawada, Goa, Jammu, Srinagar, Dehradun, Bhopal, Indore, Ludhiana, Amritsar, and others — and can facilitate delivery to the patient's treating hospital. Orders are confirmed only after receipt of a valid doctor's prescription and an import permit, where applicable.
NPP also facilitates access to other exon-skipping therapies for Duchenne muscular dystrophy, including Exondys 51 (eteplirsen) and Vyondys 53 (golodirsen), for patients whose mutation matches those specific exons.
NamedPatientProgram.com (NPP) can source Amondys 45 from reliable global channels and facilitate supply to patients, doctors, and hospitals under applicable legal provisions. As a temperature-sensitive biologic, Amondys 45 requires cold-chain handling throughout transit and must be kept refrigerated between 2°C to 8°C until use. All prescriptions are dispensed and checked by registered pharmacists and dispatched from New Delhi, India, after legal requirements are fulfilled.
For Amondys 45 cost in India and availability, contact NPP via WhatsApp at +91 98104 69557 | Toll-Free: 1800-1200-365 or email info@namedpatientprogram.com.
Patients across India can access Amondys 45 through regulated import pathways, with delivery arranged to the treating hospital based on a valid neurologist's prescription and confirmed exon 45 genetic testing.
A major healthcare hub with leading neurology centers, Mumbai coordinates access to advanced DMD therapies like Amondys 45 for eligible patients.
As part of the Delhi NCR region, the city has a strong concentration of neuromuscular disease specialists, making it a key location for accessing exon-skipping treatments.
With a growing network of multispecialty hospitals, Bangalore supports access to Amondys 45 through structured import pathways guided by treating specialists.
Home to several reputed neurology practices, Chennai facilitates access to Amondys 45 for patients with exon 45-amenable Duchenne muscular dystrophy.
A growing hub for specialty care, Hyderabad supports coordinated access to Amondys 45 for eligible patients under specialist supervision.
Eastern India's leading medical centers in Kolkata coordinate Amondys 45 access for patients with DMD.
With an expanding base of neurology clinics, Pune facilitates timely access to Amondys 45 under prescription.
Gujarat's leading hospitals support regulated access to Amondys 45 for eligible patients.
Kerala's healthcare network, including major hospitals in Kochi, coordinates access to advanced genetic therapies like Amondys 45.
Serving North India, Chandigarh's specialist centers facilitate access to Amondys 45 for patients from Punjab, Haryana, and Himachal Pradesh.
Rajasthan's leading hospitals support patient access to Amondys 45 through the Named Patient Program.
A key referral center for North India, Lucknow facilitates coordinated access to Amondys 45 under specialist care.
Odisha's growing specialty healthcare sector supports patient access to Amondys 45.
As a referral hub for the North-East, Guwahati facilitates access to Amondys 45 for patients across the region.
Access can also be coordinated for patients in other major Indian cities, subject to a valid prescription and regulatory requirements.
Written By: Nitin Goswami, Senior Medical Content Writer
Last Updated: 08 September 2026
Sources: FDA • CDSCO
Medically Reviewed By: Shilpi Banerjee, Registered Pharmacist (M.Pharm)
Last Updated: 08 September 2026
Our specialists are here to guide you through every step of the medicine access process.
Mail Us At:
info@namedpatientprogram.comContact Us:
+91 9654860915Send us a message
